Epizyme, Inc.
Epizyme, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Epizyme, Inc. is not a good value stock. Epizyme, Inc. is not very popular among insiders. Epizyme, Inc. is a mediocre stock to choose.
Log in to see more information.
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, developm...
News
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Globe Newswire Transaction focused on lead asset Tazverik(tazemetostat), a first-in-class EZH2ainhibitor approved in the U.S.Acquisition to bolster Ipsens growing oncology presence and leverage its infrastructureIpsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per ...\n more…
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022
Globe Newswire Extension allows for satisfaction of the HSR Condition as outlined in the Merger AgreementEpizyme stockholders are encouraged to tender their shares to the offer today PARIS, FRANCE, 5 August 2022 Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its ...\n more…